REGNRegeneron Pharmaceuticals, Inc.

$81B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2.3B+31.6% YoY

Gross Profit

$2.0B85.5% margin

Operating Income

$1.1B45.9% margin

Net Income

$842M36.7% margin

EPS (Diluted)

$7.39

QoQ Revenue Growth

+17.5%

Cash Flow

Operating Cash Flow

-$254M

Free Cash Flow

-$408M

Stock-Based Comp.

$101M

Balance Sheet

Total Assets

$16.1B

Total Liabilities

$6.0B

Stockholders' Equity

$10.1B

Cash & Equivalents

$1.6B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.3B	$1.7B	+31.6%
Gross Profit	$2.0B	$1.5B	+33.8%
Operating Income	$1.1B	$739M	+42.6%
Net Income	$842M	$670M	+25.8%

Revenue Segments

Product

$1.5B100%

REGN Q3 2020 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena